https://orcid.org/0000-0002-9030-183X
Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Sam Polesie, Farzad Alinaghi & Alexander Egeberg. (2023) A systematic review investigating at what proportion clinical images are shared in prospective randomized controlled trials involving patients with psoriasis and biological agents. Journal of Dermatological Treatment 34:1.
Read now
Read now
Isabel Belinchon Romero, Almudena Mateu Puchades, Miguel Ribera Pibernat, Diana. P. Ruiz Genao, Pablo de la Cueva Dobao & Jose Manuel Carrascosa. (2023) Criteria used to define tumor necrosis factor-alpha inhibitors failure in patients with moderate-to-severe psoriasis: a systematic literature review. Annals of Medicine 55:1, pages 1335-1345.
Read now
Read now
Lluís Rusiñol, Elena Carmona-Rocha & Lluís Puig. (2023) Durability and long-term outcomes of biologic therapies in psoriasis. Expert Review of Clinical Immunology 0:0, pages 1-12.
Read now
Read now
Francesco Bellinato, Paolo Gisondi & Giampiero Girolomoni. (2021) Latest Advances for the Treatment of Chronic Plaque Psoriasis with Biologics and Oral Small Molecules. Biologics: Targets and Therapy 15, pages 247-253.
Read now
Read now
Paolo Gisondi, Davide Geat, Andrea Conti, Paolo Dapavo, Stefano Piaserico, Clara De Simone, Luca Bianchi, Antonio Costanzo, Piergiorgio Malagoli, Giovanna Malara, Giuseppe Micali, Luigi Naldi, Annamaria Offidani, Annalisa Patrizi, F. Prignano, Aurora Parodi, Franco Rongioletti, Piergiacomo Calzavara-Pinton & Giampiero Girolomoni. (2020) TNF-α inhibitors biosimilars as first line systemic treatment for moderate-to-severe chronic plaque psoriasis. Expert Review of Clinical Immunology 16:6, pages 591-598.
Read now
Read now
Monica Rosales Santillan, Peyton C. Morss, Martina L. Porter & Alexa B. Kimball. (2020) Biologic therapies for the treatment of hidradenitis suppurativa. Expert Opinion on Biological Therapy 20:6, pages 621-633.
Read now
Read now
Articles from other publishers (18)
Chenyang Yu, Yingzhao Huang, Wei Yan & Xian Jiang. (2023) A comprehensive overview of psoriatic research over the past 20 years: machine learning-based bibliometric analysis. Frontiers in Immunology 14.
Crossref
Crossref
R. Ruiz-Villaverde, M. Galán-Gutiérrez, M. Llamas-Velasco, L. Salgado-Boquete, L. Puig, P. de la Cueva & J.M. Carrascosa. (2023) [Translated article] Updated Position of the Spanish Psoriasis Group (GPs) on the Use of Biosimilar Drugs in Moderate to Severe Psoriasis. Actas Dermo-Sifiliográficas 114:6, pages T494-T501.
Crossref
Crossref
R. Ruiz-Villaverde, M. Galán-Gutiérrez, M. Llamas-Velasco, L. Salgado-Boquete, L. Puig, P. de la Cueva & J.M. Carrascosa. (2023) Actualización en el posicionamiento del Grupo Español de Psoriasis (GPS) en la utilización de medicamentos biosimilares en psoriasis moderada-grave. Actas Dermo-Sifiliográficas 114:6, pages 494-501.
Crossref
Crossref
Diamant Thaçi, Ron Vender, Menno A de Rie, Curdin Conrad, David M Pariser, Bruce Strober, Veerle Vanvoorden, Maggie Wang, Cynthia Madden, Dirk de Cuyper & Alexa B Kimball. (2023) Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial. British Journal of Dermatology 188:1, pages 22-31.
Crossref
Crossref
Martina Morelli, Marco Galluzzo, Claudia Scarponi, Stefania Madonna, Giovanni Luca Scaglione, Giampiero Girolomoni, Marina Talamonti, Luca Bianchi & Cristina Albanesi. (2022) Allelic Variants of HLA-C Upstream Region, PSORS1C3, MICA, TNFA and Genes Involved in Epidermal Homeostasis and Barrier Function Influence the Clinical Response to Anti-IL-12/IL-23 Treatment of Patients with Psoriasis. Vaccines 10:11, pages 1977.
Crossref
Crossref
Anna López‐Ferrer, Eva Vilarrasa, Susana Armesto, Jorge Santos‐Juanes, Cristina Galache, Gregorio Carretero, Antonio Sahuquillo, Laura Salgado‐Boquete, Elena del Alcázar, Alvaro González‐Cantero, Antonio Martorell, Raquel Rivera‐Díaz, Josune Mitxelena‐Ezeiza, Almudena Mateu, Isabel Belinchón, Mar Llamas‐Velasco, Josep Riera‐Monroig, Anna Lázaro, José Luis López‐Estebaranz, Ignasi Gich & Lluis Puig. (2022)
Drug survival of adalimumab biosimilars in real‐world treatment of psoriasis: A
S
panish multicenter study
. Dermatologic Therapy 35:11.
Crossref
Crossref
Elisa Guidotti, Chiara Seghieri, Bruna Vinci, Alice Borghini & Francesco Attanasio. (2022) Monitoring Appropriate Monoclonal Antibodies Prescribing via Administrative Data: An Application to Psoriasis. Pharmaceuticals 15:10, pages 1238.
Crossref
Crossref
Xiu Zhang, Shengbang Wang, Wei Wang, Liumei Song, Shuo Feng, Jingping Wang, Tong Kang, Peiwen Yang, Ning Wang, Pengju Yang, Ruimin Bai, Yongping Shao & Yan Zheng. (2022) Extracellular CIRP Upregulates Proinflammatory Cytokine Expression via the NF-kappaB and ERK1/2 Signaling Pathways in Psoriatic Keratinocytes. Mediators of Inflammation 2022, pages 1-11.
Crossref
Crossref
Francesco Bellinato, Paolo Gisondi, Elena Mason, Paolo Ricci, Martina Maurelli & Giampiero Girolomoni. (2022) Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis. Dermatology and Therapy 12:6, pages 1303-1311.
Crossref
Crossref
Paolo Gisondi, Davide Geat, Martina Maurelli, Luca Degli Esposti, Francesco Bellinato & Giampiero Girolomoni. (2022) Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease. Vaccines 10:5, pages 646.
Crossref
Crossref
Eduardo Mysler, Valderilio Feijó Azevedo, Silvio Danese, Daniel Alvarez, Noriko Iikuni, Beverly Ingram, Markus Mueller & Laurent Peyrin-Biroulet. (2021) Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?. Drugs 81:16, pages 1859-1879.
Crossref
Crossref
Jen-Chih Tseng, Yung-Chi Chang, Chun-Ming Huang, Li-Chung Hsu & Tsung-Hsien Chuang. (2021) Therapeutic Development Based on the Immunopathogenic Mechanisms of Psoriasis. Pharmaceutics 13:7, pages 1064.
Crossref
Crossref
Courtney E. Heron, Rima I. Ghamrawi, Esther A. Balogh & Steven R. Feldman. (2020) Immunogenicity of Biologic and Biosimilar Therapies for Psoriasis and Impact of Novel Immunoassays for Immunogenicity Detection. American Journal of Clinical Dermatology 22:2, pages 221-231.
Crossref
Crossref
Claudia Grellmann, Wojciech Dombrowsky, Volker Fabricius, Robert Suruki, Anna Sheahan & Lars Joeres. (2020) Epidemiology and Treatment of Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis in Germany: A Real-World Evidence Study. Advances in Therapy 38:1, pages 366-385.
Crossref
Crossref
P. Gisondi, C. Virga, S. Piaserico, A. Meneguzzo, G. Odorici, A. Conti & G. Girolomoni. (2020) Switching from one infliximab biosimilar (CT‐P13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis. British Journal of Dermatology 183:2, pages 397-398.
Crossref
Crossref
Shamarke Esse, Kayleigh J. Mason, Adele C. Green & Richard B. Warren. (2020) Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases. JAMA Dermatology 156:7, pages 787.
Crossref
Crossref
Quoc-Bao D. Nguyen, Caroline T. Starling & Adelaide A. Hebert. (2020) The Use of TNFα Inhibitors in Treating Pediatric Skin Disorders. Pediatric Drugs 22:3, pages 311-319.
Crossref
Crossref
Archana Kumari, Deo Nandan Prasad, Sahil Kumar & Rajesh K. Singh. (2020) Clinical Benefits of Switching from Original Infliximab to its Biosimilar (CT-P13) as a Potential TNF-α Inhibitor. Journal of Exploratory Research in Pharmacology 000:000, pages 1-9.
Crossref
Crossref